Business Context and Reporting Period
TruGolf Holdings, Inc. (formerly Deep Medicine Acquisition Corp.; Nasdaq: TRUG) filed this Form 8-K regarding a securities purchase agreement executed on February 2, 2024. The filing was signed on February 7, 2024. The transaction provides financing for the Company through senior convertible notes and warrants.
Key Financial Terms and Metrics
- Maximum note principal: Up to $15.5 million of senior unsecured convertible notes.
- Initial closing: $4.65 million principal issued for $4.185 million of gross proceeds, reflecting a 10% original issue discount.
- Potential additional mandatory closings: $4.65 million principal for $4.185 million of proceeds, followed by $6.2 million principal for $5.58 million of proceeds, subject to specified registration, shareholder-approval, and other conditions.
- Optional investor purchases: Investors may purchase up to an aggregate $10.85 million of additional notes, subject to the agreement’s conditions and an August 2, 2024 election deadline.
- Interest: 10% annually, generally payable in shares, cash, or a combination at the Company’s option; share-paid interest bears a 15% rate. The rate increases to 15% upon an uncured event of default.
- Maturity: Five years from each issuance date, subject to potential holder extensions and earlier conversion or redemption.
- Initial conversion price: $10.00 per share, subject to adjustment provisions, including reductions based on specified market prices or lower-priced issuances. Certain adjustment prices use floors of $2.00 for $5.0 million of principal and $2.50 for the remainder.
- Warrants: Series A warrants initially covering 1,409,091 shares with a $13.00 exercise price and five-year term; Series B warrants initially covering 1,550,000 shares with a $10.00 exercise price and 30-month term. Both are subject to adjustment and dilution provisions.
- Redemptions: Holders may receive a 25% premium following specified events of default and in bankruptcy situations, and a 5% premium upon a change of control. The Company also has a limited all-notes optional redemption right.
- Revenue, profit, cash flow, margins, existing debt, and liquidity: The filing does not provide operating financial statements or clear values for these metrics.
Material Changes Versus the Prior Comparable Period
- The February 2, 2024 purchase agreement replaced the November 2, 2023 and December 7, 2023 loan agreements, which contemplated up to $11.0 million of loans, convertible notes, and warrants.
- The new financing expands the potential note principal to $15.5 million and adds specified Series A and Series B warrants.
- The notes and warrants create potential dilution through conversion, exercise, price-reset, anti-dilution, and additional share issuance provisions.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The Company must file a Form S-3 registration statement covering resale of the underlying shares generally within 30 days after the initial closing, subject to an extension in certain circumstances, and must meet specified effectiveness deadlines.
- The Company agreed to hold a special shareholder meeting by April 1, 2024 to seek Nasdaq-required approval for issuance of shares underlying the notes and warrants. Until approval and applicable Nasdaq limits are satisfied, share issuance may be restricted.
- Conversion following an event of default may occur at the lesser of the stated conversion price or 90% of the lowest VWAP during the preceding five trading days, creating potentially substantial dilution.
- Events of default include payment failures, trading or listing issues, registration delays, conversion or warrant-delivery failures, and bankruptcy or insolvency.
- The notes rank senior to the Company’s subordinated indebtedness and pari passu with other non-subordinated indebtedness. They are obligations of the Company, not its subsidiaries.
- The transaction was conducted as an unregistered private placement under Securities Act Section 4(a)(2) and Regulation D.
- The filing provides no management revenue or earnings guidance and no operating outlook beyond the financing arrangements.
Important Facts for Investors to Verify
- Whether the initial closing occurred and the actual amount of notes and warrants issued.
- Whether the additional mandatory or optional tranches were funded and the resulting principal balance.
- The status of the Form S-3 registration statement and whether it became effective within the required deadlines.
- Whether shareholder approval was obtained and how Nasdaq issuance limits affect conversions and warrant exercises.
- The Company’s current cash balance, operating cash burn, existing indebtedness, and ability to satisfy interest, redemption, and maturity obligations, which are not provided in this filing.
- The potential dilution from conversions, warrant exercises, price resets, make-whole interest, and anti-dilution adjustments.